Filed Pursuant to Rule 424(b)(5)
Registration No. 333-224179
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED MARCH 4, 2021
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus Dated April 6, 2018)

7,000,000 Shares
Common Stock
This is a public offering of common stock, $0.01 par value per share, of Sun Communities, Inc. We are offering 4,000,000 shares of our common stock. In addition, we expect to enter into a forward sale agreement with Citibank, N.A., which we refer to in this capacity as the forward purchaser. In connection with the forward sale agreement, the forward purchaser or its affiliates are borrowing from third parties and selling to the underwriters an aggregate of 3,000,000 shares of our common stock (or an aggregate of 4,050,000 shares of our common stock if the underwriters’ option to purchase additional shares is exercised in full) that will be delivered in this offering.
We will receive proceeds in this offering from the sale of the shares of common stock that we are issuing and selling in this offering but we will not initially receive any proceeds from the sale of shares of our common stock by the forward purchaser. We expect to physically settle the forward sale agreement (by the delivery of shares of our common stock) and receive proceeds from the sale of those shares of our common stock upon one or more forward settlement dates no later than March 9, 2022. We may also elect to cash settle or net share settle all or a portion of our obligations under the forward sale agreement if we conclude it is in our best interest to do so. If we elect to cash settle the forward sale agreement, we may not receive any proceeds in connection with the forward sale agreement and we may owe cash to the forward purchaser in certain circumstances. If we elect to net share settle the forward sale agreement, we will not receive any proceeds in connection with the forward sale agreement, and we may owe shares of our common stock to the forward purchaser in certain circumstances. See “Underwriting – Forward Sale Agreement.”
If the forward purchaser or its affiliate does not sell on the anticipated closing date of this offering all of the shares of our common stock to be sold by it to the underwriters, we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that the forward purchaser or its affiliate did not sell and the number of shares underlying the forward sale agreement will be decreased in respect of the number of shares that we issue and sell.
Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “SUI.” The last reported sale price of our common stock on the NYSE on March 3, 2021 was $149.49 per share.
To assist us in complying with certain federal income tax requirements applicable to real estate investment trusts, or REITs, our charter contains certain restrictions relating to the ownership and transfer of our stock, including an ownership limit of 9.8%, in number of shares or value, of the issued and outstanding shares of our capital stock. See “Description of Common Stock – Restrictions on Ownership” beginning on page 8 of the accompanying prospectus.
Investing in our common stock involves risk. Before buying any of these shares, you should carefully read the discussion of material risks of investing in our common stock referred to in “Risk Factors” beginning on page S-7 of this prospectus supplement and page 3 of the accompanying prospectus, as well as under the heading “Risk Factors” contained in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2020.
Neither the Securities and Exchange Commission, or SEC, nor any state securities commission or other regulatory body has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| | | | | | | | |
| | Per Share | | | Total | |
Public offering price | | $ | | | | $ | | |
Underwriting discount1 | | $ | | | | $ | | |
Proceeds, before expenses, to us2 | | $ | | | | $ | | |
2 | We expect to receive net proceeds from the sale of the shares of our common stock, before fees and estimated expenses, of $ , including from the initial issuance and sale by us of 4,000,000 shares of our common stock to the underwriters and upon full physical settlement of the forward sale agreement, which we expect to occur no later than March 9, 2022. For the purposes of calculating the aggregate net proceeds to us, we have assumed that the forward sale agreement will be fully physically settled based on the initial forward sale price of $ per share, which is the public offering price less the underwriting discount shown above. The forward sale price is subject to adjustment pursuant to the terms of the forward sale agreement, and the actual proceeds, if any, to us will be calculated as described in this prospectus supplement. Although we expect to settle the forward sale agreement entirely by the full physical delivery of shares of our common stock in exchange for cash proceeds, we may elect cash settlement or net share settlement for all or a portion of our obligations under the forward sale agreement. See “Underwriting – Forward Sale Agreement” for a description of the forward sale agreement. |
We have granted the underwriters a 30-day option from the date of this prospectus supplement, exercisable in whole or in part from time to time, to purchase up to an additional 1,050,000 shares of our common stock at the initial price to the public less the underwriting discount, subject to certain adjustments. Upon any exercise of such option, we will use our commercially reasonable best efforts to enter into additional forward sale agreements with the forward purchaser in respect of the number of shares that are subject to the exercise of such option. Unless the context requires otherwise, the term “forward sale agreement” as used in this prospectus supplement includes any additional forward sale agreements that we enter into in connection with the exercise, by the underwriters, of their option to purchase additional shares of our common stock. In the event that we enter into any additional forward sale agreement, if the forward purchaser or its affiliates does not deliver and sell all of the shares of our common stock to be sold by it in connection with the exercise of such option, we will issue and sell to the underwriters a number of shares of our common stock equal to the number of shares that the forward purchaser or its affiliates does not deliver and sell, and the number of shares underlying the forward sale agreement will not be increased in respect of the number of shares that we issue and sell.
The underwriters expect to deliver the shares to purchasers on or before March , 2021.
Book-Running Managers
| | | | |
Citigroup | | | | BofA Securities |
| | |
BMO Capital Markets | | J.P. Morgan | | RBC Capital Markets |
March , 2021